Benitec Biopharma Inc. BNTC
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -7.32% | -0.83% | -32.04% | -1.82% | 39.28% |
| Total Depreciation and Amortization | 4.20% | -0.83% | 1.69% | 0.00% | 11.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -17.56% | 2.89% | 42.45% | -15.21% | -21.11% |
| Change in Net Operating Assets | 752.19% | -140.57% | 77.85% | 105.61% | -258.06% |
| Cash from Operations | -10.94% | -17.90% | -12.68% | 59.20% | -166.14% |
| Capital Expenditure | -426.67% | -36.36% | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -426.67% | -36.36% | -- | -- | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -52.47% | -99.51% | -- | -- | -90.75% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 99.98% | -- | -- | 96.79% |
| Cash from Financing | -52.37% | -99.48% | -- | -- | -90.27% |
| Foreign Exchange rate Adjustments | 82.09% | 49.24% | -253.49% | 171.67% | -471.43% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -18.89% | -104.27% | 2,988.55% | 41.58% | -122.27% |